Chatterjee Debolina, Sivashanmugam Karthikeyan
School of Biosciences and Technology, Vellore Institute of Technology SBST, Vellore, Tamil Nadu, India.
Front Microbiol. 2024 Dec 20;15:1505571. doi: 10.3389/fmicb.2024.1505571. eCollection 2024.
The emergence and re-emergence of multi-drug-resistant (MDR) infectious diseases have once again posed a significant global health challenge, largely attributed to the development of bacterial resistance to conventional anti-microbial treatments. To mitigate the risk of drug resistance globally, both antibiotics and immunotherapy are essential. Antimicrobial peptides (AMPs), also referred to as host defense peptides (HDPs), present a promising therapeutic alternative for treating drug-resistant infections due to their various mechanisms of action, which encompass antimicrobial and immunomodulatory effects. Many eukaryotic organisms produce HDPs as a defense mechanism, for example Purothionin from plant, Defensins, Cathelicidins, and Histatins from humans and many such peptides are currently the focus of research because of their antibacterial, antiviral and anti-fungicidal properties. This article offers a comprehensive review of the immunomodulatory activities of HDPs derived from eukaryotic organisms including humans, plants, birds, amphibians, reptiles, and marine species along with their mechanisms of action and therapeutic benefits.
多重耐药(MDR)传染病的出现和再次出现再次给全球健康带来了重大挑战,这在很大程度上归因于细菌对传统抗菌治疗产生了耐药性。为了降低全球耐药风险,抗生素和免疫疗法都至关重要。抗菌肽(AMPs),也被称为宿主防御肽(HDPs),由于其多种作用机制,包括抗菌和免疫调节作用,为治疗耐药感染提供了一种有前景的治疗选择。许多真核生物产生HDPs作为一种防御机制,例如植物中的麦胚硫因、人类的防御素、杀菌肽和组蛋白,并且许多此类肽目前因其抗菌、抗病毒和抗真菌特性而成为研究的焦点。本文全面综述了源自包括人类、植物、鸟类、两栖动物、爬行动物和海洋物种在内的真核生物的HDPs的免疫调节活性及其作用机制和治疗益处。